Literature DB >> 15804920

FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.

Gaël Chételat1, Francis Eustache, Fausto Viader, Vincent De La Sayette, Alice Pélerin, Florence Mézenge, Didier Hannequin, Benoît Dupuy, Jean-Claude Baron, Béatrice Desgranges.   

Abstract

The accurate prediction, at a pre-dementia stage of Alzheimer's disease (AD), of the subsequent clinical evolution of patients would be a major breakthrough from both therapeutic and research standpoints. Amnestic mild cognitive impairment (MCI) is presently the most common reference to address the pre-dementia stage of AD. However, previous longitudinal studies on patients with MCI assessing neuropsychological and PET markers of future conversion to AD are sparse and yield discrepant findings, while a comprehensive comparison of the relative accuracy of these two categories of measure is still lacking. In the present study, we assessed the global cognitive decline as measured by the Mattis scale in 18 patients with amnestic MCI over an 18-month follow-up period, studying which subtest of this scale showed significant deterioration over time. Using baseline measurements from neuropsychological evaluation of memory and PET, we then assessed significant markers of global cognitive change, that is, percent annual change in the Mattis scale total score, and searched for the best predictor of this global cognitive decline. Altogether, our results revealed significant decline over the 18-month follow-up period in the total score and the verbal initiation and memory-recall subscores of the Mattis scale. The percent annual change in the total Mattis score significantly correlated with age and baseline performances in delayed episodic memory recall as well as semantic autobiographical and category word fluencies. Regarding functional imaging, significant correlations were also found with baseline PET values in the right temporo-parietal and medial frontal areas. Age and right temporo-parietal PET values were the most significant predictors of subsequent global cognitive decline, and the only ones to survive stepwise regression analyses. Our findings are consistent with previous works showing predominant delayed recall and semantic memory impairment at a pre-dementia stage of AD, as well as early metabolic defects in the temporo-parietal associative cortex. However, they suggest that only the latter predictor is specifically and accurately associated with subsequent cognitive decline in patients with MCI within 18 months of first assessment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804920     DOI: 10.1080/13554790490896938

Source DB:  PubMed          Journal:  Neurocase        ISSN: 1355-4794            Impact factor:   0.881


  48 in total

1.  Matrix-Similarity Based Loss Function and Feature Selection for Alzheimer's Disease Diagnosis.

Authors:  Xiaofeng Zhu; Heung-Il Suk; Dinggang Shen
Journal:  Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit       Date:  2014-06

2.  Subspace Regularized Sparse Multitask Learning for Multiclass Neurodegenerative Disease Identification.

Authors:  Xiaofeng Zhu; Heung-Il Suk; Seong-Whan Lee; Dinggang Shen
Journal:  IEEE Trans Biomed Eng       Date:  2015-08-11       Impact factor: 4.538

3.  Prediction of conversion from mild cognitive impairment to Alzheimer disease based on bayesian data mining with ensemble learning.

Authors:  R Chen; K Young; L L Chao; B Miller; K Yaffe; M W Weiner; E H Herskovits
Journal:  Neuroradiol J       Date:  2012-03-01

Review 4.  MNESIS: towards the integration of current multisystem models of memory.

Authors:  Francis Eustache; Béatrice Desgranges
Journal:  Neuropsychol Rev       Date:  2008-02-29       Impact factor: 7.444

5.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

Authors:  Susan M Landau; Danielle Harvey; Cindee M Madison; Robert A Koeppe; Eric M Reiman; Norman L Foster; Michael W Weiner; William J Jagust
Journal:  Neurobiol Aging       Date:  2009-08-05       Impact factor: 4.673

6.  Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.

Authors:  Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

Review 7.  Current and future uses of neuroimaging for cognitively impaired patients.

Authors:  Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

Review 8.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

9.  Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.

Authors:  Liana G Apostolova; Paul M Thompson; Steve A Rogers; Ivo D Dinov; Charleen Zoumalan; Calen A Steiner; Erin Siu; Amity E Green; Gary W Small; Arthur W Toga; Jeffrey L Cummings; Michael E Phelps; Daniel H Silverman
Journal:  Mol Imaging Biol       Date:  2009-07-28       Impact factor: 3.488

10.  Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Authors:  Katsutoshi Furukawa; Nobuyuki Okamura; Manabu Tashiro; Masaaki Waragai; Shozo Furumoto; Ren Iwata; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.